预约演示
更新于：2025-01-21
Sildenaifl Citrate
枸橼酸西地那非
更新于：2025-01-21
概要
基本信息
简介伟哥可以放松血管壁中的肌肉，增加流向身体特定部位的血液。伟哥用于治疗男性勃起功能障碍（阳痿）。 西地那非的另一个品牌是 Revatio，用于治疗肺动脉高压和提高男性和女性的运动能力。 此页面包含伟哥的特定信息，而不是 Revatio。 西地那非通过阻断磷酸二酯酶 5 (PDE5) 发挥作用，PDE5 是一种促进 cGMP 分解的酶，可调节阴茎中的血流。 它需要性唤起才能起作用。 它还会导致肺部血管扩张。 辉瑞公司最初是在 1989 年发现这种药物的，当时正在寻找治疗与心脏相关的胸痛的方法。 它于 1998 年在美国和欧盟被批准用于医疗用途。 |
药物类型 小分子化药 |
别名 Pahtension、Revatio OD、sildenafil + [41] |
靶点 |
作用机制 PDE5A抑制剂(磷酸二酯酶-5A抑制剂) |
在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-03-27), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、孤儿药 (日本)、孤儿药 (韩国)、临床急需境外新药 (中国) |
登录后查看时间轴
结构/序列
分子式C28H38N6O11S |
InChIKeyDEIYFTQMQPDXOT-UHFFFAOYSA-N |
CAS号171599-83-0 |
关联
663
项与 枸橼酸西地那非 相关的临床试验NCT06522854
Oral Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings: A Randomized Pilot Feasibility Trial
NCT06377098
Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-Resource Settings: A Randomized Pilot Feasibility Trial: Pilot Randomized Intrapartum Sildenafil in Mothers
NCT06289881
A Bioequivalence Study of Sildenafil 100 mg Tablets Relative to Viagra 100 mg Tablets in Healthy Thai Male Volunteers Under Fasting Condition
100 项与 枸橼酸西地那非 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸西地那非 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸西地那非 相关的专利（医药）
登录后查看更多信息
8,094
项与 枸橼酸西地那非 相关的文献（医药）2025-04-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Identification of Phosphodiesterase type 5 inhibitors (PDE5is) analogues using surface-enhanced Raman scattering and machine learning algorithm
Article
作者: Huang, Jiadong ; He, Hongyuan ; Li, Yujing ; Luan, Yujing
Phosphodiesterase type 5 inhibitors (PDE5is), primarily used for the treatment of erectile dysfunction, have been severely misused in recent years, posing a threat to public health and safety. This study developed a method that combines Surface-enhanced Raman spectroscopy (SERS) with machine learning algorithms to rapidly identify different PDE5is types. A total of 948 SERS spectra from 79 PDE5is were collected using gold nanoparticles (AuNPs) as the enhancement agent, and dimensionality reduction was performed through principal component analysis (PCA). Subsequently, six traditional machine learning models, partial least squares discriminant analysis (PLS-DA), orthogonal partial least squares discriminant analysis (OPLS-DA), support vector machines (SVM), k-nearest neighbors (KNN), random forest (RF), and multilayer perceptron (MLP) were applied for data classification and identification. Results showed that the MLP model achieved the highest classification accuracy of 99.65 %, with only 1.82 % of the samples misclassified from thiosildenafil to sildenafil analogues, significantly outperforming the other models. This method offers a rapid, cost-effective, and accurate alternative for the detection of PDE5is in health foods, with implications for improving regulatory oversight and public health safety.
2025-01-15The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians4区 · 医学
Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital
4区 · 医学
Article
作者: Khalid, Adeel ; Kamran, Amber ; Amin, Fatima ; Shaikh, Abdul Sattar ; Kumari, Veena ; Patel, Najma ; Rafiq, Nida ; Tebha, Sameer Saleem
INTRODUCTION:
The prevalence of persistent pulmonary hypertension of newborn (PPHN) has been estimated 1.9/1000 live births. Although the efficacy of inhaled nitric oxide and extracorporeal membrane oxygenation in PPHN is well established but it is difficult to administer and monitor in resource limited countries. Owing to this, other treatment options need to be evaluated.
METHOD:
This is a prospective observational study conducted in the Pediatric Cardiology Department, NICVD, Karachi, from February 2020 to October 2020 after the approval from the Institutional Ethical Review Committee. All the neonates referred to our Unit were screened by echocardiography (echo) and those who fulfilled the inclusion criteria were included. Echo were done before starting sildenafil and after 72 h to assess the pressure gradient across tricuspid valve and right to left or bidirectional shunt across patent ductus arteriosus , patent foramen ovale , or both. Sildenafil was started with a dose of 1 mg/kg/dose thrice a day and increased to 2 mg/kg/dose after 48 h if partial pressure of oxygen (PO1] did not increase. In neonates who did not respond to increased dose of Sildenafil were added on oral Bosentan 1 mg/kg/dose twice a day.
RESULTS:
Total 82 newborns were enrolled. Fifty-two patients improved after 48 h so were continued on same treatment. Sildenafil dose was increased in 30 (37.9%) patients whose PO2 did not increase to at least 10% from baseline after 48 h of starting treatment. Three patients expired within 48-72 h. Out of 27 remaining patients, only four responded whereas 23 patients did not show any improvement. In these patients, Bosentan was supplemented along with sildenafil.
CONCLUSION:
The results of our study show effectiveness of oral Sildenafil in treating PPHN. The overall improvement observed in the patients was overwhelming. Combination of Sildenafil with Bosentan is beneficial in patients who did not respond on Sildenafil alone.
2025-01-01Journal of Managed Care & Specialty Pharmacy
Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment
Review
作者: Simone, Laura ; Atcheson, Sara ; Stinchon, Michael R. ; Nathan, Steven D. ; Nelson, Marykate
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is a complex condition in which 2 consequential diseases interact and increase negative outcomes. Although the pathophysiologic mechanisms of PH-ILD are not yet well understood, the pronounced effect on functional status, supplemental oxygen requirements, health care resource utilization, and mortality that frequently accompany this diagnosis are well documented. A critical feature that complicates pathophysiologic understanding of PH-ILD is that progression of the pulmonary vascular disease does not always appear to be driven by the underlying lung disease. As PH-ILD is a progressive disease, early recognition and treatment initiation have the potential to delay the increased burden it creates. Historically, therapeutic development within pulmonary hypertension has concentrated on pulmonary arterial hypertension (PAH). However, PH-ILD and PAH are categorically distinct-belonging to distinct PH groups owing to differing pathophysiological mechanisms and therapeutic implications. PAH and PH-ILD may have numerous similarities; however, when PAH therapies have been studied in patients with PH-ILD, inconclusive efficacy (bosentan, sildenafil, tadalafil, iloprost) and at times deleterious safety findings (riociguat, ambrisentan) have been observed. Despite the paucity of evidence to support PAH therapy use in this patient population, widespread off-label use of PAH therapies arose as a result of a historical lack of PH-ILD-approved treatment. Recently, inhaled treprostinil-a prostacyclin analog-has become the first therapy approved for treatment of PH-ILD. In the phase 3 INCREASE trial, inhaled treprostinil was effective in improving 6-minute walk distance (the primary endpoint; P < 0.001) as well as N-terminal pro-B-type natriuretic peptide levels (P < 0.001). The approval of inhaled treprostinil in 2022 facilitates evidence-based therapeutic management. In addition, the 7th World Symposium on Pulmonary Hypertension has recently published an extensive summary of clinical research to date in PH-ILD. The proceedings from the 7th World Symposium on Pulmonary Hypertension provide timely recommendations for investigation of PH-ILD and a framework for assessing treatment needs. The therapeutic landscape advances are poised to transform PH-ILD care and improve outcomes for patients with PH-ILD.
100 项与 枸橼酸西地那非 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺性高血压 | 日本 | 2008-01-25 | |
| 家族性肺动脉高压 | 欧盟 | 2005-10-28 | |
| 家族性肺动脉高压 | 冰岛 | 2005-10-28 | |
| 家族性肺动脉高压 | 列支敦士登 | 2005-10-28 | |
| 家族性肺动脉高压 | 挪威 | 2005-10-28 | |
| 与先天性心脏病相关的肺动脉高压 | 欧盟 | 2005-10-28 | |
| 与先天性心脏病相关的肺动脉高压 | 冰岛 | 2005-10-28 | |
| 与先天性心脏病相关的肺动脉高压 | 列支敦士登 | 2005-10-28 | |
| 与先天性心脏病相关的肺动脉高压 | 挪威 | 2005-10-28 | |
| 与结缔组织病相关的肺动脉高压 | 欧盟 | 2005-10-28 | |
| 与结缔组织病相关的肺动脉高压 | 冰岛 | 2005-10-28 | |
| 与结缔组织病相关的肺动脉高压 | 列支敦士登 | 2005-10-28 | |
| 与结缔组织病相关的肺动脉高压 | 挪威 | 2005-10-28 | |
| 肺动脉高压 | 美国 | 2005-06-03 | |
| 勃起功能障碍 | 美国 | 1998-03-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心脏衰竭 | 临床3期 | 加拿大 | 2018-03-12 | |
| 低氧性呼吸衰竭 | 临床3期 | 美国 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 比利时 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 加拿大 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 丹麦 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 法国 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 德国 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 意大利 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 荷兰 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 挪威 | 2013-08-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 193 | 艱憲衊憲淵艱遞築構餘(餘範繭醖繭膚顧鑰糧觸) = 構積製繭醖願蓋簾構鹹 壓願醖壓齋築選選窪獵 (獵獵鬱憲齋選廠鑰夢衊 ) 更多 | 积极 | 2024-07-31 | ||
Placebo | 艱憲衊憲淵艱遞築構餘(餘範繭醖繭膚顧鑰糧觸) = 夢夢願觸膚選憲鹽鹽襯 壓願醖壓齋築選選窪獵 (獵獵鬱憲齋選廠鑰夢衊 ) 更多 | ||||||
早期临床1期 | 20 | (Sildenafil) | 繭艱窪築築鑰醖鏇顧範(衊蓋壓鬱憲淵製廠積獵) = 願網憲衊鏇獵糧膚夢夢 鏇繭鏇範鹽鬱鹹艱簾艱 (鹽淵構遞獵遞襯選獵壓, 艱製糧鏇築餘憲憲餘選 ~ 窪願糧繭窪艱繭簾夢膚) 更多 | - | 2024-07-10 | ||
Placebo Oral Tablet (Placebo Oral Tablet) | 繭艱窪築築鑰醖鏇顧範(衊蓋壓鬱憲淵製廠積獵) = 鹽餘鏇鏇願淵選壓夢獵 鏇繭鏇範鹽鬱鹹艱簾艱 (鹽淵構遞獵遞襯選獵壓, 糧鹽窪積夢餘淵鹽構鏇 ~ 鏇艱艱醖築觸顧簾遞繭) 更多 | ||||||
临床2期 | 75 | 艱積製壓膚淵簾鏇積積(艱獵壓範選鬱鏇淵構選) = 構簾構鬱壓構憲淵淵鬱 膚夢齋製夢蓋壓積繭餘 (鹹網餘鹽網襯鬱膚顧艱, 0.5 ~ 3.15) 更多 | 积极 | 2024-07-05 | |||
临床4期 | 385 | Sildenafil 80 mg TID | 繭願構衊選遞構醖糧選(網積顧壓遞夢淵憲顧齋): HR = 0.51 (95% CI, 0.22 ~ 1.21), P-Value = <0.001 更多 | 非劣 | 2024-06-18 | ||
Sildenafil 5 mg TID | |||||||
临床2期 | - | 艱壓廠艱獵鏇積鬱膚簾(襯憲鹽蓋鏇鹹範襯憲願) = 構積糧壓願齋構遞獵憲 窪願築積壓獵鏇窪鏇積 (繭夢製積鹽鹽壓簾憲鏇, 0.62) | 积极 | 2024-06-18 | |||
Placebo | 艱壓廠艱獵鏇積鬱膚簾(襯憲鹽蓋鏇鹹範襯憲願) = 膚顧範製蓋遞獵壓鑰窪 窪願築積壓獵鏇窪鏇積 (繭夢製積鹽鹽壓簾憲鏇, 0.04) | ||||||
临床1期 | 晚期恶性实体瘤 PDE5 expression in tumor samples | 29 | 齋鏇憲壓鑰蓋獵構窪壓(壓簾膚襯獵製膚鬱餘構) = The most common toxicities included palmar-plantar erythrodysesthesia syndrome (20 patients, 69%) and hypophosphatemia (18 patients, 62%). 壓鹽艱鏇窪積壓願廠憲 (齋獵簾醖鬱襯膚憲鏇壓 ) 更多 | 积极 | 2024-03-08 | ||
临床1期 | 24 | 膚網窪憲艱廠顧獵範廠(選鹽範廠鏇鹹蓋鬱鹽壓) = A mild decrease in blood pressure was reported in 2 of the 8 neonates after initial dose, but not with subsequent doses 顧廠壓鑰襯襯鹽簾膚網 (憲顧衊範膚築築鑰簾艱 ) 更多 | 积极 | 2024-03-01 | |||
临床2期 | - | 簾齋膚膚衊範選憲積憲(壓鏇願醖選膚壓積齋夢): P-Value = 0.02 ~ 0.05 更多 | 积极 | 2023-11-01 | |||
Placebo | |||||||
N/A | 68 | 範襯鑰壓鏇構簾鬱製窪(構選鑰糧觸夢鬱鑰窪築) = 蓋襯齋糧齋衊廠壓憲簾 遞範蓋鏇觸糧構壓選淵 (簾選襯選鬱顧憲餘選艱 ) | - | 2023-08-27 | |||
Control (without sildenafil) | 範襯鑰壓鏇構簾鬱製窪(構選鑰糧觸夢鬱鑰窪築) = 憲鹽範衊構鏇淵構遞淵 遞範蓋鏇觸糧構壓選淵 (簾選襯選鬱顧憲餘選艱 ) | ||||||
临床3期 | 277 | 鬱窪蓋艱壓糧鑰廠鏇選(鏇鹹鬱壓積選衊襯壓齋) = Placebo-corrected mean increases in walk distance of 45-50 meters were observed with all doses of sildenafil. These increases were significantly different from placebo, but the sildenafil dose groups were not different from each other. 淵鏇憲網繭選醖鬱醖襯 (膚壓顧築衊壓鹹獵襯襯 ) 更多 | 积极 | 2023-04-28 | |||
placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用